Detalhe da pesquisa
1.
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients.
Eur J Haematol
; 108(3): 178-189, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34716957
2.
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma.
Am J Hematol
; 97(12): 1607-1615, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36198076
3.
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients.
Int J Mol Sci
; 23(20)2022 Oct 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36293315
4.
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma.
Hematol Oncol
; 39(1): 41-50, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33085797
5.
Successful treatment of bilateral endogenous Fusarium solani endophthalmitis in a patient with acute lymphocytic leukaemia.
Mycoses
; 61(1): 53-60, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28872724
6.
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma.
Ann Hematol
; 96(12): 2071-2078, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-29063955
7.
Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma.
Expert Rev Anticancer Ther
; 24(6): 379-395, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38798125
8.
Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma: a challenging and happy ending fight.
Leuk Res Rep
; 21: 100399, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38078287
9.
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features.
Nat Commun
; 15(1): 1551, 2024 Feb 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38378709
10.
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients.
Cells
; 13(8)2024 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38667272
11.
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients.
Clin Exp Med
; 23(8): 5227-5239, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37815734
12.
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma.
Front Oncol
; 13: 1208741, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37305577
13.
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents.
Haematologica
; 102(3): e104-e107, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27909220
14.
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases.
Front Oncol
; 12: 1001048, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36276072
15.
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials.
Front Oncol
; 12: 890376, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35924160
16.
Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients.
Expert Rev Hematol
; 14(12): 1085-1098, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34602012
17.
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study.
Leuk Lymphoma
; 62(8): 1897-1906, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33733993
18.
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens.
Leuk Lymphoma
; 57(9): 2058-64, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-26763357
19.
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma.
Clin Cancer Res
; 21(19): 4384-90, 2015 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26078390
20.
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma.
Bone Marrow Transplant
; 55(9): 1865-1867, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32103147